Cure My Disease

Don't miss your cure!

 Log in / Sign up

530 canadians with kidney disease share real-world drug results

NCT ID NCT02925221

Completed Knowledge-focused Sponsor: Otsuka Canada Pharmaceutical Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 530 adults with autosomal dominant polycystic kidney disease (ADPKD) who were already taking the drug tolvaptan (JINARC™). Researchers wanted to see how the medication affected their quality of life, pain, and daily activities, as well as how long it took before they needed dialysis or a kidney transplant. The study did not test a new treatment—it simply observed real-world experiences to better understand the drug's impact.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant polycystic kidney disease kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)

Contacts and locations

Locations

  • Study site

    Edmonton, Alberta, Canada

  • Study site

    London, Ontario, Canada

  • Study site

    Ottawa, Ontario, Canada

  • Study site

    Toronto, Ontario, Canada

  • Study site

    Montreal, Quebec, Canada

  • Study site

    Québec, Quebec, Canada